Abstract
This study reports on the displacement of Alpha (B.1.1.7) by Delta (B.1.617.2 and its substrains AY.1, AY.2, and AY.3) in the United States. By analyzing RT-qPCR testing results and viral sequencing results of samples collected across the United States, we show that the percentage of SARS-CoV-2 positive cases caused by Alpha dropped from 67% in May 2021 to less than 3.0% in just 10 weeks. We also show that the Delta variant has outcompeted the Iota (B.1.526) variant of interest and Gamma (P.1) variant of concern. An analysis of the mean quantification cycles (Cq) values in positive tests over time also reveal that Delta infections lead to a higher viral load on average compared to Alpha infections, but this increase is only 2 to 3x on average for our study design. Our results are consistent with the hypothesis that the Delta variant is more transmissible than the Alpha variant, and that this could be due to the Delta variant’s ability to establish a higher viral load earlier in the infection compared to the Alpha variant.
Competing Interest Statement
A.B., E.T.C., S.L., S.W., D.W., A.D.R., H.M., T.C., S.J., K.M.S.B., K.T., J.N., J.M.R., E.S., X.W., D.W., D.B., M.L., J.T.L., M.I., N.L.W. and W.L. are employees of Helix.
Funding Statement
This work has been funded in part by CDC BAA contracts 75D30121P10258 (Illumina, Helix). This work was also funded in part by Helix internal funds.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Helix data analyzed and presented here were obtained through IRB protocol WIRB#20203438, which grants a waiver of consent for a limited dataset for the purposes of public health under section 164.512(b) of the Privacy Rule (45 CFR 164.512(b)).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
1) We updated the manuscript with newer sequences and SGTF information from the past month (up to July 27, 2021) 2) We added the analysis of Cq (quantification thresholds) from 370,000 RT-qPCR results to assess whether Delta infections led to higher viral loads. This is now in Figure 2 of the paper. 3) We removed previous Figure 2 and the analysis of growth rate by county vaccination rate. The comparison with Gamma growth rate became difficult as Gamma is also being replaced by Delta as we show now in Figure 1. For the growth of Delta cases by vaccination rate, we did not have enough sequences from counties with different enough vaccination rates. The analysis of growth of case numbers by county vaccination rate can be seen on CDC website. 4) We added Data tables in supplementary material that allow anyone to replicate the figures in the paper.
Data Availability
Data used in this manuscript are available from the Data tables in supplementary material. It can also be accessed on Helix Github COVID page: https://github.com/myhelix/helix-covid19db. Sequences are also available on GISAID.
